Your browser is no longer supported. Please, upgrade your browser.
Settings
CTLT [NYSE]
Catalent, Inc.
IndexS&P 500 P/E44.44 EPS (ttm)3.11 Insider Own0.30% Shs Outstand170.40M Perf Week-2.03%
Market Cap24.18B Forward P/E34.94 EPS next Y3.95 Insider Trans-39.81% Shs Float169.81M Perf Month14.51%
Income531.40M PEG2.68 EPS next Q0.65 Inst Own- Short Float1.28% Perf Quarter24.97%
Sales4.00B P/S6.05 EPS this Y174.00% Inst Trans3.13% Short Ratio2.70 Perf Half Y32.86%
Book/sh22.98 P/B6.01 EPS next Y13.23% ROA6.20% Target Price140.91 Perf Year64.16%
Cash/sh5.53 P/C25.00 EPS next 5Y16.60% ROE15.00% 52W Range79.65 - 142.64 Perf YTD32.77%
Dividend- P/FCF- EPS past 5Y28.60% ROI9.50% 52W High-3.13% Beta1.41
Dividend %- Quick Ratio1.90 Sales past 5Y16.70% Gross Margin33.80% 52W Low73.47% ATR2.80
Employees17300 Current Ratio2.40 Sales Q/Q25.40% Oper. Margin20.30% RSI (14)68.53 Volatility1.97% 2.27%
OptionableYes Debt/Eq0.83 EPS Q/Q17.90% Profit Margin13.30% Rel Volume2.03 Prev Close138.26
ShortableYes LT Debt/Eq0.81 EarningsAug 30 BMO Payout0.00% Avg Volume804.66K Price138.17
Recom1.70 SMA204.10% SMA5012.26% SMA20023.77% Volume1,610,546 Change-0.07%
Dec-10-20Upgrade KeyBanc Capital Markets Sector Weight → Overweight $120
Jun-25-20Initiated Argus Buy $100
Apr-21-20Initiated RBC Capital Mkts Outperform $65
Mar-02-20Initiated Deutsche Bank Hold
Oct-17-19Resumed Stephens Overweight $56
Aug-28-19Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Jun-21-19Upgrade Jefferies Hold → Buy $50 → $62
Apr-16-19Upgrade UBS Neutral → Buy $43 → $54
Nov-07-18Upgrade First Analysis Sec Neutral → Outperform $47 → $43
Oct-09-18Initiated UBS Neutral
Mar-28-18Upgrade KeyBanc Capital Mkts Sector Weight → Overweight
Mar-21-18Upgrade Raymond James Mkt Perform → Outperform
Feb-06-18Downgrade Stephens Overweight → Equal-Weight
Sep-21-17Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-13-17Initiated Needham Hold
Sep-08-17Downgrade KeyBanc Capital Mkts Overweight → Sector Weight
Dec-01-16Initiated Goldman Neutral
Oct-20-16Initiated KeyBanc Capital Mkts Overweight $29
Jun-21-16Upgrade Wells Fargo Market Perform → Outperform
Jun-20-16Upgrade BofA/Merrill Neutral → Buy
Sep-16-21 09:26AM  
Sep-07-21 04:05PM  
07:45AM  
Aug-31-21 01:23PM  
07:02AM  
Aug-30-21 03:30PM  
02:35PM  
12:29PM  
10:31AM  
10:21AM  
10:00AM  
08:25AM  
07:21AM  
07:10AM  
07:00AM  
07:00AM  
07:00AM  
07:00AM  
05:00AM  
04:33AM  
04:12AM  
04:05AM  
Aug-25-21 11:31AM  
Aug-24-21 10:11AM  
Aug-23-21 03:00PM  
10:50AM  
Aug-16-21 10:10AM  
Aug-06-21 09:00AM  
Aug-03-21 09:00AM  
Jul-29-21 10:05AM  
Jul-28-21 09:06AM  
Jul-27-21 01:00PM  
08:07AM  
Jul-26-21 12:12PM  
02:42AM  
Jul-22-21 11:32AM  
Jul-21-21 02:14PM  
12:00AM  
Jul-15-21 10:43AM  
10:07AM  
Jul-14-21 09:52AM  
Jul-07-21 09:00AM  
Jul-06-21 11:28AM  
Jul-02-21 07:56AM  
Jun-29-21 11:34AM  
Jun-28-21 11:24AM  
Jun-25-21 10:02AM  
Jun-09-21 11:00AM  
Jun-04-21 09:00AM  
Jun-03-21 08:33AM  
May-28-21 08:48AM  
May-21-21 08:45AM  
May-13-21 08:59AM  
May-11-21 07:00AM  
May-10-21 04:44PM  
May-07-21 09:00AM  
06:53AM  
May-06-21 03:13PM  
May-04-21 03:00PM  
08:35AM  
06:59AM  
Apr-23-21 02:22AM  
Apr-21-21 05:39PM  
Apr-19-21 08:30AM  
Apr-13-21 08:59AM  
Apr-12-21 04:49PM  
Apr-07-21 08:00AM  
Apr-06-21 09:00AM  
06:46AM  
06:26AM  
06:24AM  
Mar-31-21 06:52PM  
Mar-29-21 01:58PM  
Mar-25-21 09:50AM  
06:00AM  
Mar-24-21 02:13AM  
Mar-23-21 02:32PM  
11:53AM  
Mar-22-21 07:15AM  
Mar-18-21 02:58AM  
Mar-17-21 08:00PM  
09:37AM  
09:21AM  
Mar-16-21 08:00PM  
Mar-15-21 06:01AM  
Mar-02-21 01:30PM  
Mar-01-21 02:52PM  
02:46PM  
Feb-25-21 12:46PM  
Feb-24-21 04:10PM  
Feb-19-21 04:15PM  
Feb-18-21 01:15PM  
Feb-16-21 04:02PM  
Feb-11-21 11:40AM  
Feb-10-21 04:49PM  
02:26PM  
07:44AM  
01:19AM  
Feb-09-21 12:45PM  
10:03AM  
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hopson RickyVP, Chief Accounting OfficerAug 27Sale131.131,471192,89419,398Aug 30 09:42 PM
Schmidt Kay ASVP, Technical OperationsAug 27Sale131.13825108,18315,969Aug 30 09:43 PM
Castellano Thomas PSVP, Chief Financial OfficerAug 27Sale131.132,093274,45817,705Aug 30 09:43 PM
Maselli AlessandroPresident & COOAug 27Sale131.133,743490,82425,899Aug 30 09:41 PM
Pravda RicardoSVP & Chief HR OfficerAug 27Sale131.1369290,74212,835Aug 30 09:42 PM
Grippo Michael JSVP, Strategy & Corp. Dev.Aug 27Sale131.131,698222,66114,557Aug 30 09:40 PM
Gunther ScottSVP, Quality & Reg. AffairsAug 27Sale130.784,173545,72518,062Aug 30 09:41 PM
Chiminski John RChair & CEOAug 27Sale131.0644,4885,830,711229,872Aug 30 09:39 PM
Fasman Steven LSVP & General CounselAug 27Sale131.136,111801,34474,588Aug 30 09:39 PM
Gennadios AristipposPresident Softgel & Oral TechAug 27Sale131.132,262296,61957,481Aug 30 09:40 PM
Arnold JonathanPres. Oral & Specialty Deliv.Aug 27Sale131.1345259,27146,745Aug 30 09:38 PM
Pravda RicardoSVP & Chief HR OfficerJul 26Sale113.0545851,77710,612Jul 28 04:28 PM
Hopson RickyVP, Chief Accounting OfficerJul 26Sale113.0536040,69816,056Jul 28 04:28 PM
Schmidt Kay ASVP, Technical OperationsJul 26Sale113.0554761,83813,319Jul 28 04:29 PM
Castellano Thomas PSVP, Chief Financial OfficerJul 26Sale113.0555562,74314,463Jul 28 04:29 PM
Grippo Michael JSVP, Strategy & Corp. Dev.Jul 26Sale113.0545150,98616,605Jul 28 04:27 PM
Gunther ScottSVP, Quality & Reg. AffairsJul 26Sale113.041,079121,96715,430Jul 28 04:27 PM
Maselli AlessandroPresident & COOJul 26Sale113.05993112,25918,625Jul 28 04:28 PM
Fasman Steven LSVP & General CounselJul 26Sale113.051,549175,11467,363Jul 28 04:26 PM
Gennadios AristipposPresident Softgel & Oral TechJul 26Sale113.0546552,56850,850Jul 28 04:27 PM
Arnold JonathanPres. Oral & Specialty Deliv.Jul 26Sale113.0512013,56638,482Jul 28 04:25 PM
Chiminski John RChair & CEOJul 26Sale113.0511,1371,259,038152,481Jul 28 04:25 PM
Fasman Steven LSVP & General CounselJul 15Sale109.864,500494,35368,912Jul 16 01:06 PM
Pravda RicardoSVP & Chief HR OfficerJun 23Sale110.582,800309,62411,070Jun 24 06:10 PM
Schmidt Kay ASVP, Technical OperationsMar 22Sale105.771,400148,07813,866Mar 23 07:27 PM
Chiminski John RChair & CEOMar 19Option Exercise42.06183,0247,698,674346,642Mar 22 02:19 PM
Chiminski John RChair & CEOMar 19Sale106.01183,02419,402,784163,618Mar 22 02:19 PM
Fasman Steven LSVP & General CounselMar 18Option Exercise38.7821,647839,44594,954Mar 22 02:20 PM
Chiminski John RChair & CEOMar 18Option Exercise36.0242,2201,520,764205,838Mar 22 02:19 PM
Chiminski John RChair & CEOMar 18Sale105.1642,2204,439,855163,618Mar 22 02:19 PM
Fasman Steven LSVP & General CounselMar 18Sale104.5321,6472,262,77073,307Mar 22 02:20 PM
Joseph WettenySVP & Chief Financial OfficerFeb 16Option Exercise52.565,000262,79954,823Feb 18 09:56 AM
Joseph WettenySVP & Chief Financial OfficerFeb 16Sale124.545,000622,68549,823Feb 18 09:56 AM
Joseph WettenySVP & Chief Financial OfficerFeb 08Sale113.734,604523,61349,823Feb 10 09:05 AM
Whitlow Ricci SPresident, CSSJan 21Sale118.8569282,2442,576Jan 25 07:17 AM
Flynn KarenPres. Biologics & CCOJan 11Sale112.302,478278,27934,544Jan 11 07:12 PM
Gunther ScottSVP, Quality & Reg. AffairsJan 06Sale104.78616,39216,509Jan 07 07:04 AM
Schmidt Kay ASVP, Technical OperationsJan 04Sale104.42737,62315,266Jan 05 09:47 PM
Whitlow Ricci SPresident, CSSJan 04Sale104.42838,6673,268Jan 05 09:47 PM
Joseph WettenySVP & Chief Financial OfficerJan 04Sale104.4217217,96054,427Jan 05 09:46 PM
Maselli AlessandroPresident & COOJan 04Sale104.4214815,45419,618Jan 05 09:46 PM
Pravda RicardoSVP & Chief HR OfficerJan 04Sale104.42788,14513,870Jan 05 09:46 PM
Gennadios AristipposPresident Softgel & Oral TechJan 04Sale104.4211011,48651,315Jan 05 09:45 PM
Grippo Michael JSVP, Strategy & Corp. Dev.Jan 04Sale104.4212613,15717,076Jan 05 09:45 PM
Gunther ScottSVP, Quality & Reg. AffairsJan 04Sale104.4212012,53016,570Jan 05 09:45 PM
Arnold JonathanPres. Oral & Specialty Deliv.Jan 04Sale104.42161,67138,602Jan 05 09:44 PM
Fasman Steven LSVP & General CounselJan 04Sale104.4218919,73573,307Jan 05 09:44 PM
Flynn KarenPres. Biologics & CCOJan 04Sale104.429910,33837,022Jan 05 09:44 PM
Gennadios AristipposPresident Softgel & Oral TechDec 21Option Exercise32.6813,662446,52661,151Dec 23 07:19 AM
Gennadios AristipposPresident Softgel & Oral TechDec 21Sale102.8413,6621,405,04451,425Dec 23 07:19 AM
Zippelius PeterDirectorNov 23Sale99.265,392,280535,237,7130Nov 25 05:53 PM
Fasman Steven LSVP & General CounselNov 11Sale100.992,425244,90173,496Nov 12 12:21 PM
Fasman Steven LSVP & General CounselOct 14Option Exercise26.1815,025393,42687,460Oct 16 06:13 PM
Fasman Steven LSVP & General CounselOct 14Sale93.095,510512,93475,921Oct 16 06:13 PM
Schmidt Kay ASVP, Technical OperationsOct 14Sale93.152,985278,04515,764Oct 16 06:13 PM
Grippo Michael JSVP, Strategy & Corp. Dev.Oct 12Sale94.991,680159,58317,202Oct 13 08:24 AM
Arnold JonathanPres. Oral & Specialty Deliv.Oct 07Option Exercise30.8439,3421,213,36477,960Oct 09 03:24 PM
Arnold JonathanPres. Oral & Specialty Deliv.Oct 07Sale91.5015,9281,457,41238,618Oct 09 03:24 PM
Gunther ScottSVP, Quality & Reg. AffairsOct 02Option Exercise36.027,347264,63926,249Oct 05 07:55 PM
Chiminski John RChair & CEOOct 02Option Exercise29.90138,1354,130,817404,337Oct 05 07:55 PM
Chiminski John RChair & CEOOct 02Sale86.01182,23115,673,809173,618Oct 05 07:55 PM
Gunther ScottSVP, Quality & Reg. AffairsOct 02Sale85.484,359372,60816,690Oct 05 07:55 PM